Updated Jul 16, 2026
ZANTE GREG is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $12.32M.
Greg Zante is the Chief Financial Officer of Viking Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders. He has been involved in multiple SEC filings related to the company's financial activities.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-01-06 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale | 1.5K | $32.09 | $48K |
| 2026-01-06 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale | 10.3K | $34.24 | $353K |
| 2026-01-06 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale | 13.9K | $33.38 | $464K |
| 2026-01-06 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale | 32.0K | $32.30 | $1.03M |
| 2026-01-06 | VKTX | Viking Therapeutics, Inc. | A — Grant or award | 32.0K | $0.00 | |
| 2026-01-06 | VKTX | Viking Therapeutics, Inc. | A — Grant or award | 41.0K | $0.00 | |
| 2025-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale | 6.2K | $35.00 | $216K |
| 2025-10-28 | VKTX | Viking Therapeutics, Inc. | A — Grant or award | 11.1K | $0.00 | |
| 2025-07-02 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale | 4.3K | $27.76 | $118K |
| 2025-07-02 | VKTX | Viking Therapeutics, Inc. | A — Grant or award | 7.7K | $0.00 | |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.2K | $81.44 | $98K |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale [10b5-1] | 8.0K | $80.65 | $643K |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale [10b5-1] | 6.0K | $79.78 | $483K |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale [10b5-1] | 15.8K | $78.69 | $1.25M |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale [10b5-1] | 23.1K | $77.68 | $1.79M |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale [10b5-1] | 9.3K | $76.94 | $713K |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale [10b5-1] | 18.6K | $75.79 | $1.41M |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale [10b5-1] | 49.7K | $74.56 | $3.70M |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | M — Option exercise [10b5-1] | 51.0K | $8.52 | $435K |
| 2024-10-28 | VKTX | Viking Therapeutics, Inc. | M — Option exercise [10b5-1] | 26.0K | $5.80 | $151K |
Greg Zante is the Chief Financial Officer of Viking Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders. He has been involved in multiple SEC filings related to the company's financial activities.…
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($12.32M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live ZANTE GREG profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.